Aloxiprin


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Pain and inflammation associated with musculoskeletal and joint disorders
Adult: 600-1200 mg tid.
Contraindications
Children <16 yr due to risk of Reye's syndrome, active peptic ulceration, haemophilia and other haemorrhagic disorders; hypersensitivity to aspirin or other NSAIDs. Pregnancy and lactation. Severe hepatic and renal dysfunction.
Special Precautions
Patients with infections, dyspepsia or known to have gastric mucosal lesions. Asthma or allergic disorders. Diabetes mellitus. Impaired renal or hepatic function. Dehydration. Uncontrolled hypertension. Precipitation of acute haemolytic anaemia in G6PD patients with high doses. Avoid prolonged use in elderly. Discontinue several days prior to scheduled surgery.
Adverse Reactions
GI disturbances; hypoprothrombinaemia, blood disorders eg, thrombocytopaenia; salicylism.
Potentially Fatal: Hepatotoxicity and hypersensitivity.
Drug Interactions
Earlier salicylate absorption and higher plasma concentrations with metoclopramide in migraine patients. Increased peak concentrations by metoprolol. Decreased peak concentrations and increased risk of GI bleeding and ulceration by corticosteroids. Antacids and absorbents increase excretion. Enhance activities of coumarin anticoagulants, sulfonylureas, zafirlukast, methotrexate, phenytoin and valproate. Concomitant use with other NSAIDs increases risk of side effects. Alcohol enhance GI effects.
Lab Interference
Thyroid function tests.
Action
Aloxiprin is a polymeric condensation product of aluminium oxide and aspirin and has actions similar to aspirin through inhibition of COX, which in turn inhibits the biosynthesis of prostaglandins and thromboxanes. It also inhibits platelet aggregation.
ATC Classification
N02BA02 - aloxiprin ; Belongs to the class of salicylic acids and derivatives agents. Used to relieve pain and fever.
B01AC15 - aloxiprin ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Disclaimer: This information is independently developed by CIMS based on aloxiprin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in